Overview

Dapagliflozin in Pulmonary Arterial Hypertension

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the effects of dapagliflozin on exercise capacity and hemodynamics in patients with pulmonary arterial hypertension

Phase:

Phase 2

Details

Lead Sponsor:

Mads Ersbøll

Treatments:

Dapagliflozin